About Us

CIRC was established by the National University of Singapore, Yong Loo Lin School of Medicine in 2015.  CIRC is dedicated to advancing precision medicine through the reliable production and supply of high-quality radiopharmaceuticals.  CIRC provides a state-of-the-art GMP Cleanroom facility for the manufacture of radiopharmaceuticals and supports a broad spectrum of needs – from early-phase clinical research to commercial-scale distribution.  Dedicated imaging facilities complement the manufacturing area and allows onsite imaging using advanced modalities such as PET-MRI and PET-CT.

Our work fuels innovation in molecular imaging, helping clinicians and researchers across the world better understand, detect and treat complex diseases. The research at CIRC focuses on disease areas relevant to Singapore and the region with the overarching objective that such research should translate into improved healthcare for the general population. In addition to manufacturing and imaging capabilities, the research group provides advanced data analysis, kinetic modelling and image reconstruction capabilities supporting disease modelling and image interpretation.

CIRC provides a platform for the production of both short-lived and long-lived radioisotopes such as Carbon-11, Fluorine-18, Gallium-68, Lutetium-177 and Actinium-225.  Leveraging our knowledge of the manufacturing and regulatory landscape, CIRC can offer tailored solutions to meet specific client requirements.  Our high-tech facility and experienced team ensure CIRC products undergo strict quality control procedures and comply to regulatory standards.

CIRC’s Mission & Vision

Mission

To provide a shared state-of-the-art national resource for translational molecular imaging research, to foster collaborations between scientists and clinicians and to support the development of human capital.

Vision

To be a leading centre for clinical molecular imaging research and to drive the development and translation of molecular imaging biomarkers and theranostics to clinical practice for improved health outcomes of the general population.

CIRC’s Focus

  • Our specific aims are to develop novel technologies and biomarkers for disease, enhance the process of drug discovery and augment diagnosis and patient management capabilities in the clinic.
  • CIRC focuses on developing multi-modal imaging and theranostic capabilities, including in the fields of neuroscience, cardiology, oncology, metabolic disorders and infectious diseases.
  • Foster a culture of learning promoting the capabilities of tracer development, molecular imaging biomarkers and theranostics to improve clinical and healthcare outcomes.
  • Navigate regulatory landscape for clinical trials and commercial products to facilitate onboarding of new theranostics radiopharmaceuticals.
  • Perform radiopharmaceutical research and development, support collaborations with clinicians and seek academic/commercial opportunities to expand access to novel theranostics in South-East Asia.